Primemd Inc (PRMD) Fair Value & Analysis
Healthcare · US · Market cap $20.3K
Primemd Inc
PRMD · US
Fair value as of: Aug 17, 2026
From 23 valuation models · updated yesterday
Fair value updated Aug 17, 2026, revised from $0.0217 to $0.0004 (−98.2%) since Aug 13, 2026. Share price +33.3% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from $0.0004 (bear) to $0.0004 (bull), base $0.0004. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 54/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range $0.0002 – $0.8800 · the $0.0004 price screens below the $0.0004 fair value. Dashed = 300-day average. As of Aug 17, 2026.
Analysis
Primemd Inc (PRMD) currently trades at $0.0004, while our model-based Fair Value estimate is $0.0004, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Trailing-twelve-month revenue stands at $70.0K. Revenue declined 57.8% year over year. It earns a return on equity of -6.9%. Net debt stands at $4.5M. Fundamentals as of Aug 17, 2026
The share trades about 64% below its 52-week high and 33% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 0%, PRMD screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings ($0.0009) versus Multiples ($0.0002). Highest evidence: Growth DCF (72).
Notify me when PRMD reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Primemd Inc., together with its subsidiaries, is engaged in the purchase and development of residential and commercial real estate properties in the United States. It also holds interests in oil and gas properties. The company was formerly known as Eagle Exploration Co. and changed its name to Primemd Inc. in June 2021.
Full company description
Primemd Inc., together with its subsidiaries, is engaged in the purchase and development of residential and commercial real estate properties in the United States. It also holds interests in oil and gas properties. The company was formerly known as Eagle Exploration Co. and changed its name to Primemd Inc. in June 2021. The company is based in Littleton, Colorado.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2004 – FY2021 · reported fiscal years
Primemd Inc reported revenue of $10.5M in FY2021 versus $39.1K in FY2004, a compound +39.0%/yr. Reported net income was $3.1M in FY2021.
Watch PRMD: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare Primemd Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Primemd Inc (PRMD) overvalued or undervalued?
What is the fair value of PRMD?
What is the quality score of PRMD?
What is the revenue of Primemd Inc (PRMD)?
What is the net profit margin of PRMD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Primemd Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.